Pfizer files for COVID-19 vaccine’s full FDA approval

Pfizer on May 7 applied for its COVID-19 vaccine’s full FDA approval for use in people ages 16 and older, as opposed to the emergency use authorization under which the shot is currently being administered.

Advertisement

Over a few weeks and on a rolling basis, Pfizer will submit data on its manufacturing sites and practices to prove the vaccine’s production is consistent and reliable. The FDA also requires submission of all pre-clinical and clinical trial data.

The drugmaker has requested priority review, meaning it is seeking a decision within six months, rather than the 10 months the FDA designates under standard review.

Pfizer’s vaccine is the first COVID-19 vaccine to be reviewed for full FDA approval.

Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit

Advertisement

Next Up in Pharmacy

Advertisement

Comments are closed.